Tags

Type your tag names separated by a space and hit enter

Evaluation of the rat bone marrow and peripheral blood micronucleus test using monocrotaline.
Mutat Res. 1997 Aug 14; 392(3):243-9.MR

Abstract

The present study was performed as part of the 9th collaborative trial of the CSGMT (Collaborative Study Group for the Micronucleus Test) to evaluate the performance of the rat micronucleus test in detection of clastogenic agents. Temporary fluorescent staining using acridine orange (AO) was compared with permanent staining using a modified Feulgen technique for bone marrow and Giemsa for blood. The Feulgen and AO methods were both found to be suitable for demonstrating micronucleus induction in rat bone marrow following oral administration of monocrotaline and cyclophosphamide. Induction of micronuclei was also shown using rat blood. The simple AO supravital method described produced uniformly stained preparations which were extremely easy to assess and interpret. The AO method was preferred to Giemsa for analysis of blood, but it was essential to analyse samples within 4 days of collection to avoid excessive deterioration of cells. Because of the relatively low number of micronucleated cells found in rat blood, it is suggested that examination of a larger number of cells may be necessary to achieve a similar sensitivity to the bone marrow assay for routine screening.

Authors+Show Affiliations

Department of Cellular Toxicology, Huntingdon Life Sciences, Cambridgeshire, UK. ProudloR@UKOrg.Huntingdon.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9294024

Citation

Proudlock, R J., et al. "Evaluation of the Rat Bone Marrow and Peripheral Blood Micronucleus Test Using Monocrotaline." Mutation Research, vol. 392, no. 3, 1997, pp. 243-9.
Proudlock RJ, Statham J, Howard W. Evaluation of the rat bone marrow and peripheral blood micronucleus test using monocrotaline. Mutat Res. 1997;392(3):243-9.
Proudlock, R. J., Statham, J., & Howard, W. (1997). Evaluation of the rat bone marrow and peripheral blood micronucleus test using monocrotaline. Mutation Research, 392(3), 243-9.
Proudlock RJ, Statham J, Howard W. Evaluation of the Rat Bone Marrow and Peripheral Blood Micronucleus Test Using Monocrotaline. Mutat Res. 1997 Aug 14;392(3):243-9. PubMed PMID: 9294024.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the rat bone marrow and peripheral blood micronucleus test using monocrotaline. AU - Proudlock,R J, AU - Statham,J, AU - Howard,W, PY - 1997/8/14/pubmed PY - 1997/9/18/medline PY - 1997/8/14/entrez SP - 243 EP - 9 JF - Mutation research JO - Mutat Res VL - 392 IS - 3 N2 - The present study was performed as part of the 9th collaborative trial of the CSGMT (Collaborative Study Group for the Micronucleus Test) to evaluate the performance of the rat micronucleus test in detection of clastogenic agents. Temporary fluorescent staining using acridine orange (AO) was compared with permanent staining using a modified Feulgen technique for bone marrow and Giemsa for blood. The Feulgen and AO methods were both found to be suitable for demonstrating micronucleus induction in rat bone marrow following oral administration of monocrotaline and cyclophosphamide. Induction of micronuclei was also shown using rat blood. The simple AO supravital method described produced uniformly stained preparations which were extremely easy to assess and interpret. The AO method was preferred to Giemsa for analysis of blood, but it was essential to analyse samples within 4 days of collection to avoid excessive deterioration of cells. Because of the relatively low number of micronucleated cells found in rat blood, it is suggested that examination of a larger number of cells may be necessary to achieve a similar sensitivity to the bone marrow assay for routine screening. SN - 0027-5107 UR - https://www.unboundmedicine.com/medline/citation/9294024/Evaluation_of_the_rat_bone_marrow_and_peripheral_blood_micronucleus_test_using_monocrotaline_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1383-5718(97)00077-6 DB - PRIME DP - Unbound Medicine ER -